Duke researchers found that, in animal models, supporting pre-term fetuses in an artificial womb until they reach late pre-term gestational age results in brain tissue gene expression that more closely resembles that of late pre-term fetuses than those born prematurely.

Duke has a long and influential institutional history of providing electroconvulsive therapy clinical services, training clinicians to thoughtfully and effectively administer ECT, and advancing the science of ECT through cutting-edge research.

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells along an evolutionary pathway to become broadly neutralizing antibodies. Further tests in primates and humans are planned.

Diego V. Bohórquez, PhD, and Lauren Brinkley-Rubinstein, PhD, were among the nearly 400 recipients of Presidential Early Career Awards for Scientists and Engineers honors announced by The White House this week.

From pursuing climate change research to enhancing the partnership with the Veteran's Administration, and advancing the groundbreaking FDA-approved drug for low-grade gliomas developed by the team at the Preston Robert Tisch Brain Tumor Center, the achievements at the Duke University School of Medicine in 2024 have been remarkable. Watch this short video that highlights these and other milestones.

Hospitalized premature infants who received recommended two-month vaccinations had an increased risk of a short episode of apnea but no serious complications, according to a study led by Duke Health researchers.

Akankshi Munjal, PhD, assistant professor of cell biology, is driven by her fascination with watching development happen.

A report published in October 2023 and released by the American Psychological Association and ecoAmerica found “prenatal impacts of climate change can derail the normal development of physiological systems, cognitive abilities and emotional skills in ways that are sometimes irreversible.”

The Medical Physics Graduate Program recently marked its 20th anniversary. In the two decades since it was launched, the program has had global impact and national influence.

Joel Graybeal's journey with metastatic prostate cancer highlights the exceptional care he received at Duke Cancer Institute.